EUVIMEDEUVIMED entdecken
Crossref

Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases

Raheleh Heydari, Sara Fayazzadeh, Shabnam Shahrokh, Faezeh Shekari, Faraneh Farsad, Anna Meyfour iD

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Raheleh Heydari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Be…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Biomarkers, Extracellular Vesicles. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Inflammatory bowel disease (IBD) is a complex gastrointestinal disease with 2 main subtypes of Crohn’s disease (CD) and ulcerative colitis (UC), whose diagnosis mainly depends on the medical history, clinical symptoms, endoscopic, histologic, radiological, and serological findings. Extracellular vesicles (EVs) are now considered an additional mechanism for intercellular communication, allowing cells to exchange biomolecules. Long noncoding RNAs (lncRNAs) that are enriched in EVs have been defined as an ideal diagnostic biomarker for diseases. In this study, we investigated the expression differences of 5 lncRNAs in tissue and plasma EVs of active IBD patients compared with patients in the remission phase and healthy controls to introduce an EV-lncRNA as a noninvasive IBD diagnostic biomarker.

Methods

Twenty-two active IBD patients, 14 patients in the remission phase, 10 active rheumatoid arthritis (RA) patients, 14 irritable bowel syndrome (IBS) patients, and 22 healthy individuals were recruited in the discovery cohort. In addition, 16 patients with active IBD, 16 healthy controls, 10 inactive IBD patients, 12 active RA patients, and 14 IBS patients were also included in the validation cohort. The expression levels of 5 lncRNAs in tissue and EV-plasma were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) . Machine learning and receiver operating characteristic (ROC) curve analysis were performed to investigate the distinguishing ability of the candidate biomarkers.

Results

While the expression levels of lncRNAs CDKN2B-AS1, GAS5, and TUG1 were significantly downregulated, lncRNAs H19 and CRNDE were overexpressed in active IBD lesions. Expression of H19 was detected in plasma EVs whose isolation had been confirmed via dynamic light scattering, microscopy images, and western blotting. The classification results demonstrated the excellent ability of H19 in distinguishing IBD/active from IBD/remission, healthy control, RA, and IBS (area under the ROC curve = 0.95, 0.97,1, and 0.97 respectively).

Conclusions

Our study suggests that circulating EV-lncRNA H19 exhibited promising potential for the diagnosis of active IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingBiomarkersExtracellular VesiclesHumansFemaleMaleAdultCase-Control StudiesMiddle AgedColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesROC CurveArthritis, RheumatoidIrritable Bowel Syndrome

Stichwörter der Autor:innen

H19diagnosisextracellular vesiclesinflammatory bowel diseaselong noncoding RNAs

Substanzen

RNA, Long NoncodingH19 long non-coding RNABiomarkers

Autor:innen und Institutionen

  • Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Bioinformatics and Computational Omics Lab (BioCOOL), Department of Biophysics, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran.
  • Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
  • Advanced Therapy Medicinal Product Technology Development Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
  • Department of Adult Rheumatology, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Anna Meyfour

Förderung

  • Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences

Zitieren

APA

Heydari, R., Fayazzadeh, S., Shahrokh, S., Shekari, F., Farsad, F., & Meyfour, A. (2024). Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad219

Vancouver

Heydari R, Fayazzadeh S, Shahrokh S, Shekari F, Farsad F, Meyfour A. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad219

BibTeX
@article{Heydari2024,
  author = {Heydari, Raheleh and Fayazzadeh, Sara and Shahrokh, Shabnam and Shekari, Faezeh and Farsad, Faraneh and Meyfour, Anna},
  title = {Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad219}
}
Kostenlos starten →